Navigation Links
NewCardio Joins the Cardiac Safety Research Consortium

NewCardio to work closely with regulators, academia and pharmaceutical industry in the development of advanced ECG cardiac safety tools

SANTA CLARA, Calif., Jan. 22 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced it has become a member of the Cardiac Safety Research Consortium (CSRC).

The CSRC ( is a broad-based collaboration of medical product safety experts from academia, industry, and the U.S. Food and Drug Administration (FDA). It was formed in 2005 in response to the Critical Path Initiative, the FDA's premier effort to modernize the drug development process. The CSRC's primary goal is to facilitate development of new tools to improve cardiac safety assessment of medical products, especially tools to quantify arrhythmia (abnormal heart beat) risk of new drugs in development. With the FDA, the CSRC established a centralized ECG warehouse of ECGs obtained from drug clinical research studies.

NewCardio intends to be an active participant in CSRC efforts, by providing expertise and technology as needed, and by conducting targeted research and development projects, as such projects are reviewed and approved by the CSRC's Scientific Oversight Committee.

Branislav Vajdic, PhD, NewCardio's Chief Executive Officer, commented, "Both NewCardio and the CSRC are firmly committed to the goals of the FDA's Critical Path Initiative, the most important of which is to develop new technology to improve cardiac safety of drugs and other medical products. We regard membership in the CSRC as an important event in advancing our mutual goals, and we look forward to active and productive participation in CSRC efforts."

Mitchell W. Krucoff, MD, Professor of Cardiovascular Medicine at Duke University and CSRC co-chair, commented, "We welcome NewCardio's participation in the CSRC. NewCardio offers a firm commitment to advancing the CSRC's goal of improving cardiac safety, and in so doing has a unique opportunity to demonstrate the utility of its novel technology resources and expertise. We hope to have a long and productive relationship with the Company."

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K/A (No. 2) for the year ended December 31, 2007 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link:

    Investor Contact:
    Hayden IR
    Jeff Stanlis
    Partner and Vice President of Communications
    (602) 476-1821

SOURCE NewCardio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dorin Panescu Named NewCardios Chief Technical Officer
2. NewCardio Management to Host Conference Call on October 21
3. Glen C. Williams Joins eLearning Sales Team for Simbionix, Heading up Chicago Office
4. Valerie DeFillipo, Reproductive Health and Rights Expert, Joins Abt Associates
5. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
6. David Bagley Joins Histogen as President
7. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
8. Dr Stephan Rietiker Joins BioCeramic Therapeutics
9. Dr. John Stephen Osika, HIV/AIDS and Infectious Disease Expert, Joins Abt Associates
10. GEN Joins Charles Darwin 2009 Celebration
11. BioLife Solutions Joins Prestigious Biomedical Excellence for Safer Transfusion Collaborative
Post Your Comments:
(Date:11/24/2015)... York , November 24, 2015 ... a recent market research report released by Transparency Market ... to expand at a CAGR of 17.5% during the ... Prenatal Testing Market - Global Industry Analysis, Size, Volume, ... the global non-invasive prenatal testing market to reach a ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... InSphero AG, ... 3D cell culture models, has promoted Melanie Aregger to serve as Chief Operating Officer. ... Aregger served on the management team and was promoted to Head of ...
(Date:11/24/2015)... Nev. , Nov. 24, 2015  PDL BioPharma, Inc. ... P. McLaughlin , the company,s president and chief executive officer, ... Healthcare Conference next week in New York City ... occur on Tuesday, December 1, 2015 at 9:30 a.m. EST. ... Please connect to the website at least 15 minutes prior ...
(Date:11/23/2015)... 2015   Ceres, Inc . (Nasdaq: CERE ... for the fiscal year ended August 31, 2015 and ... --> --> During fiscal year 2015, ... products with a better balance of yield, energy and ... with several leading crop input providers and made significant ...
Breaking Biology Technology:
(Date:10/27/2015)... -- Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ... that they can be quantitatively analyzed with SMI,s analysis ... , October 28-29, 2015. SMI,s Automated Semantic Gaze ... tracking videos created with SMI,s Eye Tracking Glasses ...
(Date:10/26/2015)... 2015  Delta ID Inc., a company focused on ... PC devices, announced its ActiveIRIS® technology powers the iris ... launched by NTT DOCOMO, INC in Japan ... smartphone to include iris recognition technology, after a very ... in May 2015, world,s first smartphone to have this ...
(Date:10/22/2015)...  Synaptics (NASDAQ: SYNA ), a leading developer of human ... September 30, 2015. --> --> ... 66 percent over the comparable quarter last year to $470.0 million. ... million, or $0.62 per diluted share. --> ... of fiscal 2016 grew 39 percent over the prior year period ...
Breaking Biology News(10 mins):